GAM Holding AG bought a new stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) during the 2nd quarter, Holdings Channel reports. The institutional investor bought 14,115 shares of the biopharmaceutical company’s stock, valued at approximately $234,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HZNP. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 3,877 shares during the last quarter. D.A. Davidson & CO. purchased a new position in Horizon Pharma during the 1st quarter valued at $143,000. Zweig DiMenna Associates LLC purchased a new position in Horizon Pharma during the 1st quarter valued at $156,000. Quantitative Systematic Strategies LLC purchased a new position in Horizon Pharma during the 2nd quarter valued at $172,000. Finally, Strs Ohio boosted its holdings in Horizon Pharma by 74.2% during the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 4,600 shares during the period. 87.26% of the stock is currently owned by hedge funds and other institutional investors.

Shares of HZNP stock opened at $20.60 on Friday. Horizon Pharma PLC has a twelve month low of $11.17 and a twelve month high of $21.25. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of 17.46, a PEG ratio of 1.30 and a beta of 1.49. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.70 and a quick ratio of 1.63.

Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $0.48 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.17. The business had revenue of $302.84 million during the quarter, compared to analysts’ expectations of $275.51 million. Horizon Pharma had a positive return on equity of 19.05% and a negative net margin of 28.02%. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.41 EPS. equities analysts forecast that Horizon Pharma PLC will post 1.34 EPS for the current year.

A number of research firms recently issued reports on HZNP. Cantor Fitzgerald boosted their price objective on Horizon Pharma to $21.00 and gave the company an “overweight” rating in a report on Wednesday, July 25th. Morgan Stanley upped their target price on Horizon Pharma from $16.00 to $24.00 and gave the stock an “equal weight” rating in a report on Friday, August 17th. BidaskClub cut Horizon Pharma from a “buy” rating to a “hold” rating in a report on Friday, June 8th. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a report on Thursday, July 5th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $25.00 target price on shares of Horizon Pharma in a report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $21.00.

In related news, EVP Geoffrey M. Curtis sold 9,904 shares of the company’s stock in a transaction on Thursday, August 16th. The stock was sold at an average price of $20.63, for a total transaction of $204,319.52. Following the completion of the sale, the executive vice president now directly owns 28,767 shares in the company, valued at approximately $593,463.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.90% of the company’s stock.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Featured Story: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.